Most cited documents in this series:

Year	Title	Cited
	RePEc:wkh:phecon:v:13:y:1998:i:3:p:293-304 [Citation Analysis]	15
	RePEc:wkh:phecon:v:22:y:2004:i:13:p:857-876 [Citation Analysis]	5
	RePEc:wkh:phecon:v:17:y:2000:i:5:p:461-477 [Citation Analysis]	4
	RePEc:wkh:phecon:v:23:y:2005:i:7:p:651-658 [Citation Analysis]	3
	RePEc:wkh:phecon:v:26:y:2008:i:4:p:269-280 [Citation Analysis]	3
2010	Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review RePEc:wkh:phecon:v:28:y:2010:i:8:p:649-663 [Citation Analysis]	3
	RePEc:wkh:phecon:v:17:y:2000:i:5:p:501-513 [Citation Analysis]	3
	RePEc:wkh:phecon:v:23:y:2005:i:2:p:105-111 [Citation Analysis]	2
	RePEc:wkh:phecon:v:24:y:2006:i:1:p:39-41 [Citation Analysis]	2
	RePEc:wkh:phecon:v:24:y:2006:i:4:p:401-414 [Citation Analysis]	2
	RePEc:wkh:phecon:v:15:y:1999:i:3:p:291-303 [Citation Analysis]	2
	RePEc:wkh:phecon:v:22:y:2004:i:17:p:1097-1107 [Citation Analysis]	2
	RePEc:wkh:phecon:v:20:y:2002:i:4:p:257-265 [Citation Analysis]	2
	RePEc:wkh:phecon:v:29:y:2011:i:1:p:17-33 [Citation Analysis]	2
	RePEc:wkh:phecon:v:19:y:2001:i:11:p:1103-1109 [Citation Analysis]	2
	RePEc:wkh:phecon:v:23:y:2005:i:6:p:529-536 [Citation Analysis]	2
2010	The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives and their Implications for Prioritizing Public Investments in Comparative Effectiveness Research RePEc:wkh:phecon:v:28:y:2010:i:10:p:843-853 [Citation Analysis]	2
	RePEc:wkh:phecon:v:21:y:2003:i:1:p:39-48 [Citation Analysis]	2
	RePEc:wkh:phecon:v:24:y:2006:i:8:p:797-814 [Citation Analysis]	1
	RePEc:wkh:phecon:v:13:y:1998:i:1-part-2:p:127-134 [Citation Analysis]	1
2010	Using Comparative Effectiveness Research to Inform Policy and Practice in the UK NHS: Past, Present and Future RePEc:wkh:phecon:v:28:y:2010:i:10:p:799-811 [Citation Analysis]	1
	RePEc:wkh:phecon:v:21:y:2003:i:1:p:13-38 [Citation Analysis]	1
	RePEc:wkh:phecon:v:26:y:2008:i:9:p:781-798 [Citation Analysis]	1
2010	Pharmacoeconomic Evaluation in Ireland: A Review of the Process RePEc:wkh:phecon:v:28:y:2010:i:4:p:307-322 [Citation Analysis]	1
	RePEc:wkh:phecon:v:23:y:2005:i:1:p:77-91 [Citation Analysis]	1
2009	Converting the SF-12 into the EQ-5D: An Empirical Comparison of Methodologies RePEc:wkh:phecon:v:27:y:2009:i:6:p:491-505 [Citation Analysis]	1
	RePEc:wkh:phecon:v:21:y:2003:i:15:p:1113-1121 [Citation Analysis]	1
	RePEc:wkh:phecon:v:29:y:2011:i:8:p:673-685 [Citation Analysis]	1
	RePEc:wkh:phecon:v:24:y:2006:i:11:p:1055-1068 [Citation Analysis]	1
	RePEc:wkh:phecon:v:26:y:2008:i:9:p:733-744 [Citation Analysis]	1
2010	Varenicline: A Pharmacoeconomic Review of its Use as an Aid to Smoking Cessation RePEc:wkh:phecon:v:28:y:2010:i:3:p:231-254 [Citation Analysis]	1
	RePEc:wkh:phecon:v:24:y:2006:i:4:p:387-400 [Citation Analysis]	1
2009	Cost Effectiveness of Influenza Vaccination in Older Adults: A Critical Review of Economic Evaluations for the 50- to 64-Year Age Group RePEc:wkh:phecon:v:27:y:2009:i:6:p:439-450 [Citation Analysis]	1
	RePEc:wkh:phecon:v:13:y:1998:i:5:p:563-569 [Citation Analysis]	1
2010	Should Financial Incentives be Used to Differentially Reward Me-Too and Innovative Drugs? RePEc:wkh:phecon:v:28:y:2010:i:1:p:1-17 [Citation Analysis]	1
	RePEc:wkh:phecon:v:24:y:2006:i:4:p:355-371 [Citation Analysis]	1
2009	Weighting Must Wait: Incorporating Equity Concerns into Cost-Effectiveness Analysis May Take Longer than Expected RePEc:wkh:phecon:v:27:y:2009:i:12:p:983-989 [Citation Analysis]	1
	RePEc:wkh:phecon:v:25:y:2007:i:6:p:443-454 [Citation Analysis]	1
	RePEc:wkh:phecon:v:24:y:2006:i:2:p:123-139 [Citation Analysis]	1
2009	Budget-Impact Analyses: A Critical Review of Published Studies RePEc:wkh:phecon:v:27:y:2009:i:10:p:807-827 [Citation Analysis]	1
2010	Time for Cooperation in Health Economics among the Modelling Community RePEc:wkh:phecon:v:28:y:2010:i:8:p:609-613 [Citation Analysis]	1

Citing documents used to compute impact factor 11:

Year	Title	See
2011	A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness RePEc:eee:hepoli:v:100:y:2011:i:1:p:18-24	[Citation Analysis]
2011	What values do the public want their health care systems to use in evaluating technologies? RePEc:spr:eujhec:v:12:y:2011:i:4:p:285-288	[Citation Analysis]
2011	Economics of Individualization in Comparative Effectiveness Research and a Basis for a Patient-Centered Health Care RePEc:nbr:nberwo:16900	[Citation Analysis]
2011	Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care RePEc:eee:jhecon:v:30:y:2011:i:3:p:549-559	[Citation Analysis]
2011	Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets RePEc:nbr:nberwo:17226	[Citation Analysis]
2011	Co-Payment Exemptions and Reference Prices: an Empirical Study of Pharmaceutical Prices in Germany RePEc:yor:hectdg:11/18	[Citation Analysis]
2011	Current and future avoidable cost of smoking – Estimates for Sweden 2007 RePEc:eee:hepoli:v:103:y:2011:i:1:p:83-91	[Citation Analysis]
2011	To model or not to model: lessons from two vaccinations RePEc:spr:eujhec:v:12:y:2011:i:3:p:189-191	[Citation Analysis]
2011	Budget impact analysis in economic evaluation: a proposal for a clearer definition RePEc:spr:eujhec:v:12:y:2011:i:6:p:499-502	[Citation Analysis]
2011	Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients RePEc:spr:eujhec:v:12:y:2011:i:5:p:489-497	[Citation Analysis]
2011	Influenza vaccine for healthy adult workers: An issue for health authorities or employers? RePEc:eee:hepoli:v:102:y:2011:i:1:p:89-95	[Citation Analysis]

Cites in year: CiY